Top Markets
#1 XPIN Network XPIN Network +26.84%
#2 Ore Ore +23.54%
#3 Geodnet Geodnet +23.03%
#4 EXOD EXOD +22.08%
#5 Verus Coin Verus Coin +20.46%
#6 The Black Bull The Black Bull +18.54%
#7 AUKI AUKI +18.26%
#8 Binance-Peg Bitcoin Cash Binance-Peg Bitcoin Cash +17.14%
#9 Wrapped STX (Velar) Wrapped STX (Velar) +16.83%
#10 SSV Network SSV Network +16.67%
Coin of the day
XPIN Network XPIN Network
Instellingen
Taal
DUTCH
Valuta
USD
Thema
Orexo AB Orexo AB

Orexo AB

ORX
Rang in aandelen #24889
Orexo AB (publ), a specialty pharmaceutical company, develops and... Orexo AB (publ), a specialty pharmaceutical company, develops and commercializes pharmaceuticals and digital therapies in the United States, European Union, the United Kingdom, and internationally. Its products include Zubsolv tablets for the treatment of opioid use disorder; Abstral for the treatment of breakthrough pain in cancer patients; and Edluar for the treatment of insomnia. The company is developing OX124 for opioid overdose; OX125 for rescue medication and opioid overdose; OX640 to treat anaphylaxis with powder-based epinephrine; and OX-MPI for the treatment of endometriosis. Its digital therapies include deprexis for the treatment of depression; vorvida for alcohol management; and modia for opioid use disorder. The company has a collaboration agreement with Abera Bioscience AB to develop nasal powder vaccines based on the AmorphOX technology. Orexo AB (publ) was founded in 1994 and is headquartered in Uppsala, Sweden.
Aandeelprijs
$1.58
Marktkapitalisatie
$55.48M
Verandering (1 dag)
0.86%
Verandering (1 jaar)
-28.33%
Land
SE
Handel Orexo AB (ORX)

Categorie

Healthcare
Winst voor Orexo AB (ORX)
Winst in 2026 TTM: 0
Volgens de meest recente financiële verslagen van Orexo AB bedraagt de huidige winst van het bedrijf 0. In 2026 behaalde het bedrijf een winst van 0, gelijk aan de winst van 2026, die 0 bedroeg. De weergegeven winst op deze pagina is de winst vóór rente en belastingen, oftewel EBIT.
Winstgeschiedenis van Orexo AB van 2026 tot 2026
Winst aan het einde van elk jaar
Jaar Winst Wijzigen
Niet genoeg gegevens voor de verstrekte datums.
Winst van vergelijkbare bedrijven of concurrenten
Bedrijf Winst Winstverschil Land
Royalty Pharma plc Royalty Pharma plc
Royalty Pharma plc
RPRX.US
$1.35B -
US
Swedish Orphan Biovitrum AB Swedish Orphan Biovitrum AB
Swedish Orphan Biovitrum AB
SOBI.ST
- -
SE
Ipsen S.A. Ipsen S.A.
Ipsen S.A.
IPN.PA
- -
FR
Corcept Therapeutics Incorporated Corcept Therapeutics Incorporated
Corcept Therapeutics Incorporated
CORT.US
$26.37M -
US
Sino Biopharmaceutical Limited Sino Biopharmaceutical Limited
Sino Biopharmaceutical Limited
1177.HK
$992.42M -
HK